Bavarian Nordic, Janssen ally in vaccines for HPV-related cancers; Deal amended
Bavarian Nordic AS licensed Janssen Pharmaceuticals Inc. exclusive rights to use its MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop a heterologous prime-boost vaccine for human papillomavirus.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.